

# SIOP CNS GCT II – Intracranial GCTs Summary of Investigations

## Summary of Recommended Follow-up Investigations in Malignant GCTs (Germinoma and NGGCT)

Dr. Calaminus, Clinic for Pediatric Hematology and Oncology, University Children's Hospital, D – 48129 Münster

X = Required  
(X) = If indicated

internat. trial no.:

centre no.:

trial no.:

sex:

date of birth

|  | End of Treatment (6-12 weeks after EOT) | 6 months   | 9 months | 12 months (1 year) | 18 months                              | 24 months (2 years) | 3 years                                | 4 years | 5 years        |   |
|--|---|--|----------|--------------------|--|---------------------|--|---------|----------------|---|
| MRI cranial  | x                                       | x  | x        | x                  | x                                      | x                   | x                                      | x       | x              |   |
| MR Angio Germinoma   | x <sup>1</sup>                          |  |          |                    |  |                     |  |         | x <sup>1</sup> |   |
| MRI spinal   | x                                       | Performed based on symptoms or according to clinician's discretion, but at least with alternate head scans in patients with CNS involvement of their tumour at diagnosis, assuming a clear scan at the end of treatment. |          |                    |  |                     |  |         |                |   |
| Tumour marker (AFP + total HCG) Germinoma                                  | x                                       | x  | x        | x                  | x                                      | x                   | x                                      | x       | x              |   |
| Tumour marker (AFP + total HCG) NGGCT                                      | x                                       | Monthly for the 1 <sup>st</sup> year   |          |                    | 2 monthly for the 2 <sup>nd</sup> year |                     | 3 monthly for the 3 <sup>rd</sup> year |         | x              | x |
| Quality of Life assessment (* + neurocognitive assessment where performed) | x                                       |  |          |                    |  | x*                  |  |         | x              |   |
| Endocrine evaluation   |   | Timing according to local/national practice  |          |                    |  |                     |  |         |                |   |
| Ophthalmological assessment  |   |  |          |                    |  |                     |  |         |                |   |
| Hearing assessment   |   |  |          |                    |  |                     |  |         |                |   |
| GFR or creatinine clearance  |   |  |          |                    |  |                     |  |         |                |   |
| Other assessments for complications of tumour and treatment                |   |  |          |                    |  |                     |  |         |                |   |

<sup>1</sup>according to local practice (see protocol chapter 6.1.7 and 6.2.3)